Cargando…
A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
Emicizumab is a bispecific antibody mimicking the cofactor function of activated coagulation factor VIII to prevent bleeds in patients with hemophilia A. The dose selection for the first‐in‐child phase III study of emicizumab was addressed by pediatric pharmacokinetic prediction using an adult/adole...
Autores principales: | Yoneyama, Koichiro, Schmitt, Christophe, Chang, Tiffany, Dhalluin, Christophe, Nagami, Sayaka, Petry, Claire, Levy, Gallia G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298840/ https://www.ncbi.nlm.nih.gov/pubmed/34545950 http://dx.doi.org/10.1002/jcph.1968 |
Ejemplares similares
-
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2017) -
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021) -
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
por: Retout, Sylvie, et al.
Publicado: (2020) -
Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021) -
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)